Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Shares Up 0.3% - Still a Buy?

Key Points

• Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) shares rose by 0.3% to last trade at $10.56, despite an 87% decline in trading volume compared to averages.
• The company received a "sell (d-)" rating from Weiss Ratings, contributing to an overall average rating of "Sell" from analysts.
• Recent institutional investments indicate heightened interest, with Clear Street LLC increasing its stake by 265.1% in the second quarter, leading to ownership of 22,000 shares valued at $230,000.

Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) shot up 0.3% during mid-day trading on Wednesday . The stock traded as high as $10.57 and last traded at $10.56. 4,032 shares were traded during trading, a decline of 87% from the average session volume of 31,517 shares. The stock had previously closed at $10.53.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Oaktree Acquisition Corp. III Life Sciences in a report on Wednesday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of "Sell".

Oaktree Acquisition Corp. III Life Sciences Price Performance

The firm's 50-day simple moving average is $10.46 and its two-hundred day simple moving average is $10.41.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Clear Street LLC increased its position in Oaktree Acquisition Corp. III Life Sciences by 265.1% in the 2nd quarter. Clear Street LLC now owns 22,000 shares of the company's stock valued at $230,000 after acquiring an additional 15,975 shares in the last quarter. Meteora Capital LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth approximately $517,000. Kepos Capital LP acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth approximately $563,000. Picton Mahoney Asset Management acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth approximately $767,000. Finally, Radcliffe Capital Management L.P. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the 2nd quarter worth approximately $856,000.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 1995 and is headquartered in Los Angeles, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.